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Abstract
Background: As little information is available on children with non-classic presentations of Pompe disease, we
wished to gain knowledge of specific clinical characteristics and genotypes. We included all patients younger than
18 years, who had been evaluated at the Pompe Center in Rotterdam, the Netherlands, between 1975 and 2012,
excluding those with the classic-infantile form. None were treated with enzyme replacement therapy at the time of
evaluation. We collected information on first symptoms, diagnosis, use of a wheelchair and/or respirator, and
enzyme and mutation analysis and assessed muscle strength, pulmonary function, and cardiac parameters.
Results: Thirty-one patients participated. Median age at symptom onset was 2.6 years (range 0.5–13y) and at
diagnosis 4.0 years. Most first problems were delayed motor development and problems related to limb-girdle
weakness. Fatigue, persistent diarrhea and problems in raising the head in supine position were other first
complaints. Ten patients were asymptomatic at time of diagnosis. Five of them developed symptoms before
inclusion in this study. Over 50 % of all patients had low or absent reflexes, a myopathic face, and scoliosis; 29 %
were underweight. Muscle strength of the neck flexors, hip extensors, hip flexors, and shoulder abductors were
most frequently reduced. Pulmonary function was decreased in over 48 % of the patients; 2 patients had cardiac
hypertrophy. Patients with mutations other than the c.-32–13T > G were overall more severely affected, while 18
out of the 21 patients (86 %) with the c.-32–13T > G/‘null’ genotype were male.
Conclusions: Our study shows that Pompe disease can present with severe mobility and respiratory problems
during childhood. Pompe disease should be considered in the differential diagnosis of children with less familiar
signs such as disproportional weakness of the neck flexors, unexplained fatigue, persistent diarrhea and unexplained
high CK/ASAT/ALAT. Disease presentation appears to be different from adult patients. The majority of affected
children with GAA genotype c.-32–13T > G/‘null’ appeared to be male.
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Background
Pompe disease, also known as acid maltase deficiency or
glycogen storage disease type 2 (OMIM 232300), is a
lysosomal storage disorder that presents as a progressive
myopathy in which deficiency of the enzyme acid α-
glucosidase (EC 3.2.1.20) causes glycogen to accumulate
in lysosomes. Ultimately, this leads to cell destruction
[1–3]. In 1932, J.C. Pompe first described the classic-
infantile form of the disease [4]. Classic infantile patients
characteristically present shortly after birth with general-
ized and severe muscle weakness and with hypertrophic
cardiomyopathy. They do not reach major milestones
like walking and usually die within their first year of life
[5, 6]. Later, other forms were reported and Pompe dis-
ease appeared to be a continuous spectrum of closely re-
lated phenotypes with the classic-infantile form at the
most severe end of the spectrum. In the literature,
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milder phenotypes are referred to as childhood, juvenile,
adult and late-onset. Patients with these non-classic vari-
ants of Pompe disease usually have no hypertrophic car-
diomyopathy and present with a more slowly progressive
limb-girdle muscle weakness, which eventually results in
wheelchair dependency, respirator need, and shortened
life expectancy [3, 7–17].
While many publications have described the natural
history of the disease in classic-infantile and adult
Pompe patients [5, 6, 12, 14–16], there is little informa-
tion on presenting signs and symptoms in children who
do not fulfill the criteria of classic-infantile Pompe dis-
ease [18].
To gain knowledge of the presentation of Pompe dis-
ease in children and to describe their specific clinical
characteristics, we set up an observational study to col-
lect information on disease symptoms, the distribution
and severity of muscle weakness, physical limitations,
lung function, cardiac structure and function, and geno-
types of 31 children diagnosed with a non-classical pres-
entation of Pompe disease.
Methods
Subjects
This observational study included all patients under the
age of 18 years who had been diagnosed at or referred to
the Pompe Center at Erasmus MC University Medical
Center between 1975 and 2012. These patients came
from the Netherlands and abroad, and had been diag-
nosed by measurement of the acid α-glucosidase activity
in cultured fibroblasts, leukocytes or muscle biopsy
specimens, and by mutation analysis. Patients with
classic-infantile Pompe disease were not included in this
study.
Thirty-one patients participated in this cross-sectional
study. They were evaluated as part of studies approved
by the Institutional Review Board (n = 28) or as part of
routine clinical evaluation (n = 3). Medical history was
obtained at first visit. Per patient, the following data
were collected: gender, current age, geographic origin,
first symptoms, age at first symptoms, age at diagnosis,
wheelchair use, respiratory support, specific clinical find-
ings (e.g. facial muscle weakness, bulbar muscle weak-
ness, scoliosis, contractures, or muscle atrophy);
functional impairments, spirometry and weight and
height. Low body weight was defined as weight corrected
for height if under 2SD for peers. Blood tests included
measurement of creatine kinase (CK), aspartate amino-
transferase (AST), alanine aminotransferase (ALT), and
lactate dehydrogenase (LDH). A pediatrician and child
neurologist performed clinical and neurological exami-
nations in all patients. Only natural course data were in-
cluded. None of the patients had been treated with
enzyme replacement therapy.
Muscle-strength testing
Muscle strength was assessed by hand-held dynamome-
try (HHD) (n = 24) and manual muscle-strength testing
(MMT) (n = 24) [19, 20]. The following muscle groups
were tested with HHD: neck flexors, shoulder abductors,
elbow flexors, wrist extensors, hip flexors, hip abductors,
knee extensors, knee flexors, and foot dorsal flexors.
HHD scores (Newton) were expressed as percentages of
the reference values (50th percentile) for healthy peers
[20]. All percentages were cumulated and divided by 9
to obtain a total HHD sum score expressed in percent-
age of normal.
MMT was performed according to the Medical Re-
search Council guidelines [21] for the following muscle
groups: neck flexors, neck extensors, deltoid muscles, bi-
ceps, triceps, wrist extensors, hip flexors, hip extensors,
hip abductors, hip adductors, knee flexors, knee exten-
sors, and foot dorsal and plantar flexors.
Lung function testing
Lung function testing was performed by spirometry with
the patients in upright-seated position (n = 28), and su-
pine position (n = 23) according to ATS/ERS standards
[22]. The highest outcome of three reproducible tests
was used for analysis. The results were expressed as per-
centage of predicted and as a z-score, due to the para-
digm shift towards z-scores, based on reference values
corrected for age, length, gender and race [23]. A per-
centage lower than 80 % of predicted and a z-score
below −1.64 were considered abnormal. Two patients
were too young for reproducible spirometry to be reli-
able. Because of poor lung function six other patients
were unable to perform testing in a supine position and
one of them in either sitting or supine position.
Cardiac assessment
In all patients, conventional Doppler, and 2D M-mode
tracings were performed by an experienced sonographer
(JP) according to the recommendations of the American
Society of Echocardiography (Sonos 5500 ultrasound
system, Philips, Best, the Netherlands). Standard 12-lead
electrocardiograms were also made and analyzed by a
pediatric cardiologist.
Enzymatic and molecular assays
Acid α-glucosidase activity was measured in leukocytes
[24] and in cultured skin fibroblasts [13] according to
standard procedures, and was expressed in nmol/h/mg
protein. The protein concentrations of cell homogenates
was measured as described previously [25].
Genomic DNA was isolated from blood or cultured fi-
broblasts, and mutation analysis of the GAA gene was
performed according to standard procedures [13, 26].
The severity of the mutations were rated using the
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format of Kroos et al. [27], and were examined for their
effect on enzyme activity, quantity, and quality, in trans-
fected cells after site directed mutagenesis [26]. In case
of splice site mutations, the effect of the mutation was
examined using real-time PCR in mRNA, isolated from
the patients’ fibroblasts [27].
Statistics
Demographic and clinical data were summarized using
descriptive statistics including mean, SD, median, ranges,
and percentages. As the data were not normally distrib-
uted, differences between groups were analyzed using a
Mann–Whitney test. P-values < 0.05 were considered
statistically significant. All statistical analyses were per-
formed using SPSS for Windows version 21.
Results
Symptom onset and diagnosis
Thirty-one children participated in this cross-sectional
study. Table 1 shows the patient characteristics and
genotype. Twenty-two patients were male, nine were fe-
male. There were 17 patients from the Netherlands, 4
from Belgium, 5 from Germany, 3 from Greece, 1 from
Great Britain, and 1 from the United States.
The median age at which patients had experienced
their first symptom was 2.6 years (range 0.5–13y). At
time of diagnosis, their median age was 4.0 years (range
0–16y). The commonest presenting symptoms were de-
layed motor development (in nine patients), and other
symptoms related to limb-girdle weakness, such as fre-
quent falling, difficulty climbing stairs, and problems
with running and sports. Fatigue, persistent diarrhea and
problems in raising the head in supine position were
other first complaints. Median time span between symp-
tom onset and diagnosis was 0.9 years (range 0 to
5.8 years).
Ten patients had been diagnosed pre-symptomatically.
In six of them the diagnosis was made after elevated CK
and transaminase serum levels had been found during a
hospital admission for unrelated matters. The other four
patients had been diagnosed because they had a sibling
with Pompe disease. Five of these ten patients developed
symptoms between diagnosis and first examination in
our hospital (see for details Table 1).
Clinical findings
All 31 patients were evaluated in the Pompe Center at
Erasmus MC University Medical Center. Their ages at
the time of examination ranged from 0.1 to 17.1 years.
Table 2 shows the findings on clinical examination. Over
50 % of the 31 patients had low or absent reflexes, a
myopathic face, and scoliosis. Facial muscle weakness
was generally mild and did not lead to speech difficulties
or dysphagia. One exception was a patient (patient 23 in
Table 1) that had severe dysarthria and was fed via a per-
cutaneous endoscopic gastrostomy catheter. This patient
had been wheelchair bound and ventilator dependent
since the age of 6 years.
Nine patients had flexion contractures, mainly in the
ankles. Three of the nine patients had contractures of
the hips and knees. Several patients had undergone cor-
rective surgery for either contractures (n = 4, patients 1,
6, 10, 29 in Table 1), or scoliosis (n = 4, patients 7, 14,
23, 30 in Table 1). It is noteworthy that 29 % of the pa-
tients were underweight; corrected for height, their
weight was 4.3 to 2.0 standard deviations below healthy
peers.
Standardized neurological examination of all patients
showed that 70 % had one or more physical limitations.
Over 50 % of all patients had difficulties standing up
from supine position and flexing the neck in supine pos-
ition (Table 2). Other important limitations were prob-
lems with climbing stairs, rising from a chair and
standing up from sitting on their heels.
Distribution of muscle weakness
Figure 1 shows the severity of muscle weakness and in
how many patients the various muscle groups were af-
fected. The commonest weakness was in the neck
flexors, which were affected in 75 % of the patients.
Other muscles that were frequently affected were the
gluteus maximus (extension of the hip), the ileopsoas
(flexion of the hip), the biceps and the deltoid muscle.
The triceps, wrist extensors, and foot plantar flexors
were relatively unaffected. In patients with far advanced
disease, all muscles were affected.
All patients had a lower total HHD sum score than
age related peers. Total muscle strength ranged from 0–
79 % of normal (median 55 %). Four patients were
wheelchair-bound at the time of investigation; four
others became wheelchair dependent in the period
thereafter. The ages of these eight patients when they
became wheelchair dependent ranged from 4 to 22 years
(n = 8, median 7.5 years). The median time period be-
tween first symptoms and loss of ambulation was
4.5 years (n = 8, range 3 to 15 years).
Lung function testing
In all subjects, FVC values were equal or higher than
slow VC. Hence, all analyses were done on FVC. In sit-
ting position, 14 of the 29 patients (48 %) had decreased
forced vital capacity (FVC) indicated by z-score below
−1.64 (13 patients had a percentage of predicted below
80 %). In one of these patient the FVC was too low to be
measured reliably in sitting position. In supine position,
19 of the 29 (66 %) had a FVC z-score below −1.64 (18
patients had a percentage of predicted below 80 %). In 6
of these patients, lung volume was too low to be
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Table 1 Patient characteristics
Pt Sex Onset (y)g Diagnosis
(y)g
Examination
(y)g
Wheelchair
(y)
Ventilator (y) FVC z-score sitting
(% pred)
FVC z-score su-
pine (% pred)
MRC
%
CK U/l GAA activity
(nmol/h/mg)h
Allele 1 Allele 2
1a M 0.5 2.5 10.04 Yes (11) No –0.25 (97 %) –1.12 (87 %) 65 % 530 9.1 c.-32–13T > G (pm) c.525delT (vs)
2e, f F 0.8 0 0.1 No No Too young Too young n.a. 358 Deficient c.-32–13T > G (pm) c.2135 T > C (ls)
3 F 0.8 1.1 8.9 No No 0.21 (102 %) 0.1 (101 %) 89 % 1871 13.3 c.-32–13T > G (pm) c.923A > C (pls)
4e M 0.8 2 2.4 No No Too young Too young n.a. 1353 13 c.-32–13T > G (pm) c.2135 T > C (ls)
5 M 0.8 2.3 9.5 No No –1.53 (82 %) –1.71 (80 %) 98 % 550 15.4 c.-32–13T > G (pm) c.525delT (vs)
6 M 1 2 8.2 Partially (4) No –3.47 (59 %) –4.36 (48 %) 79 % 3078 4.5 c.-32–13T > G (pm) c.1051delG (vs)
7 M 1 2 13.7 No At night (12) –4.08 (54 %) –5.4 (39 %) 87 % 548 17.9 c.-32–13T > G (pm) c.525delT (vs)
8 M 1.5 2 13.3 No No –0.91 (90 %) –1.76 (80 %) 93 % 1595 16 c.-32–13T > G (pm) c.2481 + 102_2646
+ 31del (vs)
9a, f M 2 1 6.6 No No –0.97 (89 %) –1.4 (84 %) 94 % 763 11 c.-32–13T > G (pm) c.525delT (vs)
10 M 2.5 3 13 No No –3.01 (66 %) –4.09 (54 %) 84 % 1960 8.6 c.-32–13T > G (pm) c.2331 + 2 T > A (vs)
11d M 5 10.8 10.8 No No 0.2 (102 %) –0.29 (97 %) 97 % 588 11.9 c.-32–13T > G (pm) c.525delT (vs)
12 F 5 7.8 7.8 No No 0.62 (108 %) 0.35 (104 %) 100 % 1003 11.6 c.-32–13T > G (pm) c.2331 + 2 T > A (vs)
13f M 5 2 7.6 No At night (5) –1.77 (78 %) –1.72 (79 %) 100 % 436 Deficient c.-32–13T > G (pm) c.1062C > G (pls)
14 M 7 10 10.7 Yes (22) At night (16) –2.22 (75 %) Unable 80 % 540 8,9 c.-32–13T > G (pm) c.1548G > A (pls)
15f M 8 4 15.8 No No –2.65 (70 %) –3.05 (65 %) 93 % 1424 7.8 c.-32–13T > G (pm) c.1441 T > C (pls)
16f M 12 8 14.6 No No –2.43 (71 %) Unable 82 % 1808 Deficient c.-32–13T > G (pm) c.307 T > G +
c.271G > A (pls)
17 M 13 14 14.3 No No –1.68 (81 %) –1.77 (80 %) 95 % 2935 6.2 c.-32–13T > G (pm) c.1933G > A (pls)
18f M no symptoms 4 5.2 No No –1.41 (82 %) –1.96 (76 %) 97 % 677 Deficient c.-32–13T > G (pm) c.2481 + 102_2646
+ 31del (vs)
19d, f M no symptoms 13.1 13.1 No No –0.69 (92 %) –1.77 (80 %) 100 % 614 Deficient c.-32–13T > G (pm) c.525delT (vs)
20c, f M no symptoms 14 15.2 No No 3 (135 %) 1.72 (120 %) n.a. 1409 Deficient c.-32–13T > G (pm) c.307 T > G (pls)
21c, f M no symptoms 16 17.1 No No 1.29 (115 %) –0.25 (97 %) n.a. 1506 Deficient c.-32–13T > G (pm) c.307 T > G (pls)
22 M 0.5 1 1.3 Yes (4) Died (10)i –4.77 (45 %)j Unable n.a. 586 Deficient c.1798C > T (ls) c.525delT (vs)
23 F 1 1.9 12.5 Yes (6) Yes (6) Ventilator Ventilator 10 % 1381 Deficient c.875A > G (pm) unknown/r.0?
24 M 2 2.9 2.9 Yes (6) Died (6)i –5.29 (33 %)j Unable n.a. 1046 Deficient unknown c.1645G > A (pm)
25 M 2.7 3.5 5.9 No No 0.34 (104 %) 0.04 (100 %) 87 % 908 2.8 c.1634C > T (ls) c.2481 + 102_2646
+ 31del (vs)
26b F 4 4 8.1 No No 0.01 (100 %) –0.63 (92 %) 98 % 572 2.3 c.-32–3C > G (ls) c.1551 + 1G > A (vs)
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Table 1 Patient characteristics (Continued)
27b M 5 5 10.1 No No –1.38 (84 %) –2.55 (71 %) n.a. 774 1.7 c.-32–3C > G (ls) c.1551 + 1G > A (vs)
28 F 6 7 9.9 Partially (9) At night (8) –6.36 (30 %) –6.88 (25 %) 82 % 979 0.3 c.1829C > T (ls) c.1912G > T (pls)
29 F 6.5 11.6 12.7 No No –2.36 (73 %) –2.89 (67 %) 79 % 776 8.4 unknown (r.spl 2 %) c.525delT (vs)
30 F 10 11 16.4 Yes (16) Yes (12) –8.07 (13 %) Unable 72 % 1560 3.4 c.-32–3C > A (ls) c.877G > S +
c.271G > A (pls)
31f F no symptoms 15 15.9 No No 1.33 (116 %) 1.2 (115 %) 100 % 1040 2.5 c.861C > T (r.spl =
<5 %)
c.925G > A (pls)
Patients are listed by age of onset and are subdivided into two groups: those who carry the c.-32–13T > G mutation and those who do not a, b, c, d, e : Siblings; f patients who were diagnosed pre-symptomatically; g:
Age at onset, age at diagnosis, age at examination expressed in years (y); h: GAA activity was deficient in all patients. Only results obtained in cultured fibroblasts and performed with the same method at Erasmus MC
are reported; i: both patients died of respiratory failure, one at age 6, the other at age 10; j: first available lung function measurement (patient still untreated) at the ages of respectively 9 and 5.7 years; severity of the
mutation is indicated by (vs) very severe; (pls) potentially less severe; (ls) less severe; (pm) potentially mild (for more information, see www.pompecenter.nl)
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measured reliably in supine position. Lung function
measurements are displayed in z-scores and percentage
of predicted in Fig. 2. FEV1/VC ratios were normal in all
patients, indicative of a restrictive abnormality.
The median difference in FVC between sitting and su-
pine positions (postural drop) was 6.0 % (range 0 to
−18 %). Five patients were ventilator dependent at the
time of first evaluation, and one became ventilator
dependent during follow-up (see Table 1 for details). Five
of these six patients had a scoliosis. At the ages of 6 and
10 years, two other patients died from respiratory failure,
when it was decided not to start respiratory support.
The median duration from first symptoms to any kind
of respiratory support or death by respiratory insuffi-
ciency was 4.5 years (range 0 to 11 years, n = 8). The me-
dian age at start of ventilation or death was 9 years
(range 5 to 16 years, n = 8).
Cardiac evaluation
Cardiac evaluation showed abnormalities in six patients;
in three, the findings were considered to be related to
Pompe disease. Two patients had hypertrophic cardio-
myopathy without outflow-tract obstruction (patients
22, 23 in Table 1). In one patient, this had first been no-
ticed at one year of age, and in the other at two. Their
ECGs showed high amplitude QRS complexes and repo-
larization disturbances consistent with their hyper-
trophic cardiomyopathy. In addition, their ECGs and
that of a third patient (patient 3 in Table 1) showed a
short PR interval and a delta wave suggestive of Wolff-
Parkinson-White syndrome.
Minor abnormalities of the cardiac valves were noted
in three patients. The abnormalities included a quadri-
cuspid aortic valve, a minor deformity of the tricuspid
valve leading to minimal tricuspid regurgitation, and
minimal insufficiency of both atrioventricular valves.
These abnormalities were all considered to be coinciden-
tal findings and not related to Pompe disease.
Fig. 1 Distribution of skeletal muscle weakness (a) and severity of weakness of the individual muscles (b)
Table 2 Results of clinical and neurological examination
Number of patients (Total 31)
Clinical findings
Low/absent reflexes 22 (71 %)
Weakness facial muscles 16 (52 %)
Scoliosis 16 (52 %)
Muscle tone decreased 13 (42 %)
Scapular winging 12 (39 %)
Muscle atrophy 11 (35 %)
Contractures 9 (29 %)
Low body weight 9 (29 %)
Ptosis 0 (0 %)
Physical limitations
Standing up from supine position 18 (58 %)
Flexing the neck in supine position 17 (55 %)
Standing up from sitting on heels 13 (42 %)
Climbing stairs 13 (42 %)
Rising from a chair 10 (32 %)
Erecting back in prone position 8 (26 %)
Four deep tendon reflexes were tested: the biceps reflex, the triceps reflex, the
knee-jerk reflex, and the ankle-jerk reflex
van Capelle et al. Orphanet Journal of Rare Diseases  (2016) 11:65 Page 6 of 11
Enzymatic and molecular diagnosis
Table 1 shows the patients’ genotypes and the severity of
their mutations. All mutations have been described pre-
viously in the literature (www.pompecenter.nl). Twenty-
three patients (74 %) carried a potentially mild mutation
on one GAA allele and a severe mutation on the other.
Twenty-one of these patients carried the common c.-
32–13T > G splice-site mutation. Since none of the mu-
tations in the other eight patients were considered po-
tentially mild, these patients’ genotypes were considered
to be more severe. Acid α-glucosidase activity measured
in cultured fibroblasts ranged from 0.3 to 17.9 nmol/h/
mg protein (n = 21, median = 8.6; control range 45–
160 nmol/h/mg). In patients with the c.-32–13T > G/
‘null’ genotype activity ranged from 4.5 to 17.9 nmol/h/
mg (n = 14, median = 11.3) and from 0.3 to 8.4 nmol/h/
mg (n = 7, median = 2.5) in patients with the non-IVS1
genotype.
Laboratory parameters
At first visit, all patients had elevated CK levels (median
979 U/l, range 358 to 3078 U/l; normal values below 230
U/l)). Transaminase levels were elevated in all 31 patients
as well, including those who were symptom-free; AST
ranged from 82 to 610 U/l (normal values below 51 U/l),
ALT from 71–551 U/l (normal values below 39 U/l). LDH
levels were elevated in 21 out of 30 patients, ranging from
449 to 2828 U/l (normal values below 765 U/l).
Comparison of patients with the c.-32–13T > G/‘null’
genotype (IVS1) and those with other genotypes
(non-IVS1)
Comparison of the twenty-one patients with the c.-32–
13T > G/‘null’ genotype and the 10 patients with other
mutations showed no significant differences in age at first
symptoms and age at diagnosis (Table 3). Their median
age at first examination was similar. We noted that pa-
tients in the non-IVS1 group tended to have lower muscle
strength and a more severely restricted lung function in
sitting and supine positions than those in the IVS1 group.
This was in line with the fact that more non-IVS1 than
IVS1 patients had become wheelchair bound and ventila-
tor dependent at a relatively young age. In addition, the
two patients with hypertrophic cardiomyopathy belonged
to the non-IVS1 group. Another interesting observation
was that 18 out of the 21 patients (86 %) with the c.-32–
13T > G/‘null’ genotype were male, against 4 out of 10 in
the non-IVS1 group. Other than the possible trend that
patients with the c.-32–13T > G/‘null’ genotype were gen-
erally less severely affected compared to patients with
other genotypes we weren’t able to identify other genotype
- phenotype relations in the c.-32–13T > G/‘null’ genotype
group.
Discussion
As little information is available on the clinical presenta-
tion of children with non-classic forms of Pompe dis-
ease, we evaluated 31 children’s clinical and molecular
characteristics. Our findings highlight that non-classic
Pompe disease can cause a significant burden in child-
hood and add to the understanding that Pompe disease
presents as a broad spectrum of clinical phenotypes.
The presentation of Pompe disease can be variable.
Children in our patient population typically presented
with weakness of the limb-girdle muscles and/or delayed
motor development; lung function was compromised in
approximately half of them, and 2 patients whose muscle
function deteriorated very rapid also had hypertrophic
cardiomyopathy.
Nevertheless, the diagnosis of Pompe disease should
also be considered in children whose symptoms are less
typical, such as disproportional weakness of the neck
a b
Fig. 2 FVC z-score (a) and percentage of predicted (b) in sitting and supine position
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flexors, unexplained fatigue, persistent diarrhea, and an
elevation of transaminase levels. Independent of whether
the children had symptoms or not, all patients partici-
pating in the study had elevated CK, ALT and AST
values. It should be noted, however, that in rare cases
CK, ALT and AST may be normal, as we very recently
encountered in a childhood onset patient (personal com-
munication) and as was earlier described for about 10 %
of adult patients [28].
Although respiratory problems did not precede prox-
imal muscle weakness in any of the children, lung func-
tion was already significantly restricted in 48 % of the
cases. In 26 % of the affected children, respiratory insuf-
ficiency either led to the need for ventilator support or
resulted in death during childhood. This finding signifies
the importance of early monitoring of lung volume by
means of spirometry in children affected by Pompe dis-
ease as also advised in adults [17, 29].
Lung function tests are best performed in both sitting
and supine positions, as 9 patients had postural drops
suggestive of diaphragm weakness. This is a well-known
feature of Pompe disease, and contributes to the onset
of nocturnal hypoventilation [29, 30]. Since a recent
study in children with neuromuscular disorders found
that daytime lung function and nocturnal hypoxemia
were poorly correlated, we suggest to regularly perform
sleep studies as an additional tool for identifying chil-
dren with nocturnal hypoventilation [31].
Twenty-two of the 31 children that we investigated
were male. Interestingly, among them were 18 with the
c.-32–13T > G/‘null’ genotype that is most common
among adult patients (against only 3 of the 9 female pa-
tients). In two studies that focused on disease variation
among children and adults with the c.-32–13T > G/‘null’
genotype, the male-to-female distribution was equal (55
and 58 % males, respectively). However, neither study
focused on any potential difference in age at onset be-
tween male and female patients [12, 13]. The present
study indicates the existence of such a gender difference.
Our earlier analysis of 225 published case reports on
children and adults with Pompe disease also showed a
predominance of males (67 %) in patients under 18 years
old [11]. Previous studies reported that pulmonary func-
tion was more affected in males than in females [17],
and that more men than women had bulbar involvement
and shoulder-girdle muscle weakness [17]. A study com-
paring phenotypes in siblings with Pompe disease also
confirmed that males were more severely affected than
females [32].
Since Pompe disease is inherited as an autosomal re-
cessive trait, there has been no satisfactory explanation
to date why males with the same GAA genotype as fe-
males would present at an earlier age. This finding
seems to suggest that the clinical expression of Pompe
disease involves secondary gender-related factors. Gen-
der differences have also been reported for other neuro-
muscular disorders such as facioscapulohumeral
muscular dystrophy and some subtypes of limb-girdle
muscular dystrophy [33–35]. One muscle related differ-
ence between men and women found so far is that
women with limb girdle muscular dystrophy type 2A
and 2B showed less muscle fiber atrophy compared to
males [35]. This may also apply in Pompe disease.
Though other causes have been suggested, such as dif-
ferences in genetic and epigenetic factors, the exact
mechanism remains elusive.
Our findings are fully consistent with the broad spectrum
of clinical phenotypes associated with the c.-32–13T > G/
‘null’ GAA genotype [12, 13]. Looking at the genotype-
phenotype correlation within our group of children shows
a similar age of onset, age at diagnosis, and current age for
all different genotypes. Several patients were wheelchair
Table 3 Comparison of patients with the c.-32–13T > G mutation and other mutations at the time of examination
All c.-32–13T > G Other mutations P-value
Patients 31 21 10 –
M/F 22/9 18/3 4/6
Age first symptom (median) 2.6 (0.5–13) 2 (0.5–13) 4.0 (0.5–10) 0.6
Age diagnosis (median) 4.0 (0–16) 3.0 (0–16) 4.5 (1–15) 0.6
Age at examination (median) 10.1 (0.1–17.1) 10.7 (0.1–17.1) 10 (1.3–16.4) 0.7
Disease duration (median) 5.1 (0.8–12.7) 6.5 (1.3–12.7) 4.1 (0.8–11.5) 0.2
Diagnosed pre-symptom. 10 9 1 –
Still symptom free 5 4 1 –
HHD sumscore (%) 55 (n = 24) 58 (n = 18) 36 (n = 6) 0.02
FVC pred sitting (%)a 82 82 58 0.15
FVC pred supine (%)a 79 80 55 0.08
Disease duration is calculated as time between the presentation of first symptoms and first examination in our hospital
aFor patients who didn’t perform lung function testing in supine position the value obtained in sitting position was used. For one patient using 24 h invasive
ventilation a value of 0 % was used in the analyses
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bound and/or ventilator dependent despite of having the
c.-32–13T > G/‘null’ genotype, which is mostly associated
with adult onset disease. The c.-32–13T > G, is a leaky
splice site mutation that results in the formation of 10–
20 % of normally processed alpha-glucosidase protein and
activity, which explains the later onset non-classic pheno-
type in patients c.-32–13T > G/‘null’ genotype. In our
group of patients the second mutation (severe, less severe
or potentially less severe) did not seem to have an effect
on the age of presentation. This is in line with earlier stud-
ies of Kroos et. al., Wens et.al. and Montalvo et. al. also
showing a broad variation of phenotypes among patients
with the c.-32–13T > G/null genotype. It was hypothe-
sized that epigenetic factors and environmental factors in-
fluence the level of disease severity [12, 13, 32]. More
research is required.
At a group level, children in the non-IVS1 group seem
to be more severely affected than patients with the 32-13T
> G/‘null’ genotype. This is illustrated by two specific pa-
tients in the non-IVS1 group who had hypertrophic car-
diomyopathy and became fully wheelchair bound; one at
the age of 4 years and the other at the age of 6. The first
child died from respiratory failure at the age of 10. The
other child became completely ventilator dependent when
she was 6 years old. These two patients expressed a
phenotype that Slonim et al. previously called the “atypical
infantile form” of Pompe disease [18].
Overall, the genotypes identified in the non-IVS1
group were more severe than those in the IVS1 group
(see Table 1 and www.pompecenter.nl). Some of the ge-
notypes have been described in the literature, such as
the genotype c.1634C > T/c.2481 + 102_2646 + 31del
(our patient 25). The c.1634C > T (ls) in combination
with a very severe mutation was previously described in
three patients. One of those patients presented at the
age of one year, became dependent on respiratory sup-
port at the age of 20, and was wheelchair bound at the
age of 23 [15]. The second patient was diagnosed at
16 years of age, and began to use a walking stick at 19.
Pulmonary function worsened at the age of 17–19 years
and vital capacity dropped to 26 % of predicted and be-
came respirator dependent at the age of 20 years [36].
The third patient presented at the age of 13 years with
pronounced limb girdle weakness and died at the age of
18 years [37]. The similarities in clinical course of these
previously reported cases are remarkable, and if the
genotype-phenotype correlation holds for our patient,
who was only 6 years old at time of examination, he car-
ries a high probability to develop severe respiratory and
mobility problems before adulthood. Such information
may be relevant when it is time to decide when to start
enzyme replacement therapy.
Children and adults share a wide variation of disease
presentation and disease progression, and a similar
involvement of respiratory and proximal skeletal muscles
[8, 9, 12–16]. Although the distribution of muscle weak-
ness shows a limb-girdle pattern in both children and
adults, there are also differences. While the neck flexors
are by far the most severely affected muscle group in
children, they are only mildly affected in adults [8, 15].
A recent MRI study performed in 20 adult patients by
Carlier et al. also showed relatively mild involvement of
the neck flexors in adults [38].
Another difference is the relative sparing of the quad-
riceps muscle in adult patients [28, 38]. In the current
population of 31 children with Pompe disease, the mus-
cles of the thigh were affected more heterogeneously,
and the quadriceps muscles were not spared. Neither
did any of our patients have ptosis, despite a recent pub-
lication in which ptosis was present in 14.7 to 23 % of
adult Pompe patients [28, 39, 40]. It should be noted
that ptosis has often been found in an early stage of the
disease, even as a presenting symptom in adult Pompe
patients. While van der Beek et al. found that patients
had difficulties with speech, chewing or swallowing,
which was suggestive of bulbar weakness in 28 % of their
patients, we found bulbar weakness in only one patient.
In contrast, 52 % of our children had scoliosis, compared
to only 21 to 23 % of adult Pompe patients [11, 28]. In
several children the scoliosis was so severe that it inter-
fered with their mobility and lung volume; four children
needed surgical correction of the spine. A cross-
sectional analysis of data from the Pompe Registry, a
large multinational observational program, found scoli-
osis to be present in 57 % of patients with childhood dis-
ease onset [41].
Our study had two main limitations. First, since the
Pompe Center at Erasmus MC University Medical Cen-
ter serves as a national and international referral center
for Pompe disease, there may be selection bias, due to
referral of patients who were more than average severely
affected. Nonetheless, ten of the 31 patients had been di-
agnosed pre-symptomatically, 5 of whom were still
symptom-free at time of evaluation. A second limitation
is the fact that the study was cross-sectional. As all chil-
dren manifesting significant symptoms of the disease,
started to receive enzyme replacement therapy during
follow-up, the approval of this therapy in 2006 interfered
with the collection of longitudinal follow-up data.
Conclusions
In conclusion, our study shows that the course of child-
hood Pompe disease varies widely, and patients may mani-
fest serious problems before adulthood. We stress that
Pompe disease should be considered in the differential
diagnosis of patients with less familiar signs such as
disproportional weakness of the neck flexors, unexplained
fatigue and persistent diarrhea. Disease presentation,
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distribution of muscle weakness, and the occurrence of
specific symptoms such as bulbar muscle weakness or
ptosis all appear to be different from those in adult
patients. Regular assessment of lung volume and sleep
studies are recommended to identify children at risk for
early respiratory insufficiency. Patients with mutations
other than the c.-32–13T > G were overall more severely
affected, which is consistent with their more severe geno-
types. The majority of affected children with GAA geno-
type c.-32–13T > G/‘null’ appeared to be male.
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